Cost-effectiveness of cervical cytologic examination during pregnancy
- PMID: 8285092
Cost-effectiveness of cervical cytologic examination during pregnancy
Abstract
Background: We undertook a study to determine the cost-effectiveness of performing routine cervical cytologic examination during pregnancy.
Methods: The costs generated by doing routine prenatal cervical cytologic examination were calculated based on chart review in a family practice setting. A consecutive sample of 523 patients giving birth during 1990 was used. Analysis was done on 423 of those patients with prenatal Papanicolaou smear results recorded. Cost savings from detection of curable disease and utility of the test in terms of well-years saved were calculated from published statistics using a single-step Markov process to model the population at risk.
Results: For patients of all ages using a discount rate of 5 percent, the cost generated by prenatal cervical cytologic examination was $146,400 per well-year of life saved. Age stratification showed cost per well-year to range from $321,600 for patients aged 15 to 19 years to $48,800 for those aged 35 to 39 years.
Conclusions: Routine prenatal cervical cytologic examination is significantly less cost-effective than the most commonly done medical procedures. If medical funding is limited, elimination of this test should be considered for women with normal findings on cervical cytologic examinations within the previous 2 to 3 years.
Similar articles
-
[Cytologic cancer prevention with smears of the uterine cervix and endocervical canal in pregnancy].Gynakol Geburtshilfliche Rundsch. 1992;32(1):40-2. doi: 10.1159/000271832. Gynakol Geburtshilfliche Rundsch. 1992. PMID: 1515780 German.
-
Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.J Natl Cancer Inst. 2002 Oct 2;94(19):1469-83. doi: 10.1093/jnci/94.19.1469. J Natl Cancer Inst. 2002. PMID: 12359856
-
Cost-effectiveness of the conventional papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors.Arch Fam Med. 2000 Aug;9(8):713-21. doi: 10.1001/archfami.9.8.713. Arch Fam Med. 2000. PMID: 10927709
-
Evaluation of costs and benefits of advances in cytologic technology. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial.Acta Cytol. 1998 Jan-Feb;42(1):69-75. doi: 10.1159/000331536. Acta Cytol. 1998. PMID: 9479325 Review.
-
Paying for prevention standardizing the measurement of the value of health care interventions.Obstet Gynecol Clin North Am. 2002 Dec;29(4):613-43, v. doi: 10.1016/s0889-8545(02)00022-0. Obstet Gynecol Clin North Am. 2002. PMID: 12509088 Review.
Cited by
-
Gynecologic malignancy in pregnancy.Obstet Gynecol Sci. 2013 Sep;56(5):289-300. doi: 10.5468/ogs.2013.56.5.289. Epub 2013 Sep 14. Obstet Gynecol Sci. 2013. PMID: 24328018 Free PMC article. Review.
-
The prevalence and course of preinvasive cervical lesions during pregnancy in a Northern Nigerian Teaching Hospital.Ann Afr Med. 2017 Apr-Jun;16(2):74-80. doi: 10.4103/aam.aam_35_16. Ann Afr Med. 2017. PMID: 28469121 Free PMC article.